In addition, the quinonemethide triterpenoid compound Pristimerin was shown to suppress VEGF-induced vasculogenesis in a prostate cancer bone metastasis model by blocking the AKT signaling in bone marrow-derived endothelial progenitor cells [138]. Here, AKT1 is linked to Familial prostate cancer.